Maven Securities’s AbbVie ABBV Stock Holding History

Maven Securities’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,530	Closed	-$3M	–	388
2025 Q4	$3.1M	Buy	+13,530	New	+$3.08M	0.07%	247
2025 Q3	–	Sell	-1,365	Closed	-$278K	–	442
2025 Q2	$253K	Sell	1,365 -1,388	-50%	-$258K	0.01%	723
2025 Q1	$577K	Sell	2,753 -7,784	-74%	-$1.51M	0.02%	555
2024 Q4	$1.87M	Sell	10,537 -2,101	-17%	-$386K	0.05%	296
2024 Q3	$2.5M	Buy	+12,638	New	+$2.36M	0.05%	313
2022 Q4	–	Sell	-8,448	Closed	-$1.3M	–	805
2022 Q3	$1.13M	Buy	+8,448	New	+$1.21M	0.02%	492
2022 Q2	–	Sell	-2,751	Closed	-$420K	–	872
2022 Q1	$446K	Sell	2,751 -2,477	-47%	-$360K	0.02%	576
2021 Q4	$708K	Sell	5,228 -4,629	-47%	-$547K	0.02%	453
2021 Q3	$1.06M	Buy	9,857 +761	+8%	+$87K	0.03%	416
2021 Q2	$1.02M	Buy	9,096 +6,162	+210%	+$694K	0.04%	426
2021 Q1	$318K	Buy	2,934 +312	+12%	+$33.4K	0.01%	789
2020 Q4	$281K	Buy	+2,622	New	+$252K	0.03%	433

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Maven Securities's ABBV Position: Q1 2026 in Review

Maven Securities sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 13,530 shares — an estimated $3M sold.

Maven Securities first reported a position in ABBV in Q4 2020 and held it in 12 quarters. The position peaked at $3.1M in Q4 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Maven Securities reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Maven Securities sold 13,530 AbbVie shares in Q1 2026, an estimated $3M.
Maven Securities first reported a position in AbbVie in Q4 2020 and held it in 12 quarters.
Maven Securities's AbbVie position peaked at $3.1M in Q4 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Maven Securities's 13F filing for Q1 2026, filed 15 May 2026.